Amneal Pharmaceuticals, Inc. (AMRX) financial statements (2022 and earlier)

Company profile

Business Address
,
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments248341151213 
Cash and cash equivalents248341151213 
Restricted cash and investments9625 
Receivables707669636529 
Inventory, net of allowances, customer advances and progress billings489491381457 
Inventory489491381457 
Prepaid expense41343538 
Contract with customer, asset1212
Other undisclosed current assets258441 
Total current assets:1,5201,5521,2101,287 
Noncurrent Assets
Finance lease, right-of-use asset645961
Operating lease, right-of-use asset605970
Property, plant and equipment514478478544 
Intangible assets, net (including goodwill)1,7601,8271,8022,081 
Goodwill593523420426 
Intangible assets, net (excluding goodwill)1,1671,3051,3831,655 
Other noncurrent assets21324468 
Other undisclosed noncurrent assets   373 
Total noncurrent assets:2,4202,4542,4563,066 
TOTAL ASSETS:3,9404,0063,6664,353 
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:583614507514 
Accounts payable131153103115 
Accrued liabilities72807766 
Employee-related liabilities62593677 
Taxes payable369  
Other undisclosed accounts payable and accrued liabilities316316283257 
Debt31442121 
Due to related parties488618 
Other undisclosed current liabilities1511150 
Total current liabilities:677677550554 
Noncurrent Liabilities
Long-term debt and lease obligation2,6802,7352,6092,670 
Long-term debt, excluding current maturities2,6802,7352,6092,631 
Capital lease obligations39 
Liabilities, other than long-term debt87864039 
Due to related parties48    
Other liabilities39864039 
Other undisclosed noncurrent liabilities112151120194 
Total noncurrent liabilities:2,8792,9722,7692,903 
Total liabilities:3,5563,6493,3193,456 
Temporary equity, carrying amount1712   
Stockholders' equity
Stockholders' equity attributable to parent, including:360303232505 
Common stock    0
Additional paid in capital658628607530 
Accumulated other comprehensive loss(25)(41)(0)(8) 
Accumulated deficit(276)(287)(378)(21) 
Receivable from shareholders or affiliates for issuance of capital stock    (0)
Other undisclosed stockholders' equity attributable to parent3333 
Stockholders' equity attributable to noncontrolling interest742115392 
Total stockholders' equity:367345347896 
TOTAL LIABILITIES AND EQUITY:3,9404,0063,6664,353 

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues2,0941,9931,6261,663 
Cost of revenue
(Cost of Goods and Services Sold)
(1,302)(1,330)(1,147)(947) 
Other undisclosed gross profit(23)(35)(126)  
Gross profit:769628353716 
Operating expenses(603)(537)(602)(533) 
Other undisclosed operating loss(14)  (203) 
Operating income (loss):15391(249)(20) 
Nonoperating income (expense)(121)(127)28(183) 
Investment income, nonoperating 07(3) 
Foreign currency transaction gain (loss), before tax(0)16(5)(20) 
Interest and debt expense(5)(9)(6)(6) 
Income (loss) from continuing operations before equity method investments, income taxes:27(44)(227)(209) 
Other undisclosed income from continuing operations before income taxes5966 
Income (loss) from continuing operations before income taxes:31(36)(220)(203) 
Income tax expense (benefit)(11)104(383)1 
Income (loss) before gain (loss) on sale of properties:2069(604)(201) 
Unusual or infrequent item, or both, net (gain) loss(5)    
Other undisclosed net income5    
Net income (loss):2069(604)(201) 
Net income (loss) attributable to noncontrolling interest(10)2224233 
Other undisclosed net income attributable to parent3  149 
Net income (loss) attributable to parent:1391(362)(20) 
Preferred stock dividends and other adjustments   (1) 
Other undisclosed net loss available to common stockholders, basic(3)    
Net income (loss) available to common stockholders, diluted:1191(362)(21) 

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):2069(604)(201) 
Comprehensive income (loss):2069(604)(201) 
Comprehensive income (loss), net of tax, attributable to noncontrolling interest(27)6523236 
Other undisclosed comprehensive income (loss), net of tax, attributable to parent34(84)19142 
Comprehensive income (loss), net of tax, attributable to parent:2750(353)(23) 

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: